Abiraterone Acetate treatment reduces fatigue in men with mCRPC
According to a retrospective analysis of data from a randomized, double-blind, Phase III clinical trial, abiraterone acetate (Zytiga™) can significantly lower levels of fatigue in men with metastatic, castration-resistant prostate cancer (as well as extending survival).
These data were presented today at the European Multidisciplinary Cancer Congress by Dr. Cora Sternberg and colleagues. They are based on a re-analysis of information collected as part of the original Phase III clinical trial that led to the approval of abiraterone acetate for treatment of men with mCRPC earlier this year.
Dr. Sternberg is quoted as stating that:
These data were presented today at the European Multidisciplinary Cancer Congress by Dr. Cora Sternberg and colleagues. They are based on a re-analysis of information collected as part of the original Phase III clinical trial that led to the approval of abiraterone acetate for treatment of men with mCRPC earlier this year.
Dr. Sternberg is quoted as stating that:
One of the most distressing issues these metastatic castration-resistant prostate cancer patients face during hormone treatment is extreme fatigue. Our results show that zytiga therapy has the potential to reduce cancer-related fatigue in this patient population, in addition to the previously demonstrated survival benefit
No comments:
Post a Comment